Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Liver Cirrhosis

  Free Subscription


22.11.2021

1 Cancer
1 Gut
1 Intern Med
14 J Hepatol
1 Minerva Gastroenterol (Torino)
3 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Cancer

  1. SHALTIEL T, Zheng S, Siderides C, Gleeson EM, et al
    Hepatitis C-positive Black patients develop hepatocellular carcinoma at earlier stages of liver disease and present with a more aggressive phenotype.
    Cancer. 2021 Feb 25. doi: 10.1002/cncr.33377.
    PubMed         Abstract available


    Gut

  2. ARMANDI A, Schattenberg JM
    NAFLD between genes and environment: what drives fibrogenesis?
    Gut. 2021;70:815-816.
    PubMed        


    Intern Med

  3. ABE K, Fujita M, Hayashi M, Takahashi A, et al
    The Efficacy of Levocarnitine Treatment in Relieving Fatigue in Patients with Cirrhosis but without Overt Hepatic Encephalopathy.
    Intern Med. 2021;60:3533-3542.
    PubMed         Abstract available


    J Hepatol

  4. DEEB M, Karlsen TH, Hirschfield GM
    The 6 C's of Primary Sclerosing Cholangitis.
    J Hepatol. 2020 Jul 7. pii: S0168-8278(20)30436.
    PubMed        

  5. ROULOT D, Brichler S, Layese R, BenAbdesselam Z, et al
    Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis Delta.
    J Hepatol. 2020 Jul 4. pii: S0168-8278(20)30441.
    PubMed         Abstract available

  6. PAPATHEODORIDIS GV, Dalekos GN, Idilman R, Sypsa V, et al
    Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
    J Hepatol. 2020 Jun 15. pii: S0168-8278(20)30382.
    PubMed         Abstract available

  7. LENS S, Baiges A, Alvarado E, LLop E, et al
    Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.
    J Hepatol. 2020 Jun 11. pii: S0168-8278(20)30368.
    PubMed         Abstract available

  8. MAK LY, Wan-Hin Hui R, Fung J, Liu F, et al
    Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B.
    J Hepatol. 2020 Jun 3. pii: S0168-8278(20)30361.
    PubMed         Abstract available

  9. GAO J, Wei B, de Assuncao TM, Liu Z, et al
    Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis.
    J Hepatol. 2020 May 7. pii: S0168-8278(20)30290.
    PubMed         Abstract available

  10. LEFERE S, Puengel T, Hundertmark J, Penners C, et al
    Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages.
    J Hepatol. 2020 Apr 29. pii: S0168-8278(20)30269.
    PubMed         Abstract available

  11. DU M, Wang X, Yuan L, Liu B, et al
    Targeting NFATc4 attenuates non-alcoholic steatohepatitis in mice.
    J Hepatol. 2020 Jul 24. pii: S0168-8278(20)30482.
    PubMed         Abstract available

  12. CALVARUSO V, Craxi A
    Hepatic benefits of HCV cure.
    J Hepatol. 2020 Aug 7. pii: S0168-8278(20)30530.
    PubMed         Abstract available


  13. EASL recommendations on treatment of hepatitis C - Final update of the series.
    J Hepatol. 2020 Aug 21. pii: S0168-8278(20)30548.
    PubMed         Abstract available

  14. PAVLIDES M, Francis S, Barnes E
    Abbreviated MRI to screen for HCC in patients with cirrhosis. A step forward but a long road ahead.
    J Hepatol. 2021 Nov 8. pii: S0168-8278(21)02169.
    PubMed        

  15. TANTAI X, Liu Y, Yeo YH, Praktiknjo M, et al
    Effect of sarcopenia on survival in patients with cirrhosis: A systematic review and meta-analysis.
    J Hepatol. 2021 Nov 13. pii: S0168-8278(21)02174.
    PubMed         Abstract available

  16. SABOO K, Petrakov NV, Shamsaddini A, Fagan A, et al
    Stool microbiota are superior to saliva in distinguishing cirrhosis and hepatic encephalopathy using machine learning.
    J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02183.
    PubMed         Abstract available

  17. BATES J, Vijayakumar A, Ghoshal S, Marchand B, et al
    Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
    J Hepatol. 2020 May 3. pii: S0168-8278(20)30281.
    PubMed         Abstract available


    Minerva Gastroenterol (Torino)

  18. XU J, Liu K, Ma Z, Lin Y, et al
    Exploration of inflammation, oxidative stress, adiponectin and intestinal flora in patients with Hepatitis B, liver cirrhosis and hepatocellular carcinoma.
    Minerva Gastroenterol (Torino). 2021 Nov 18. pii: S2724-5985.21.03063.
    PubMed        


    PLoS One

  19. CHANG Y, Han JA, Kang SM, Jeong SW, et al
    Clinical impact of serum exosomal microRNA in liver fibrosis.
    PLoS One. 2021;16:e0255672.
    PubMed         Abstract available

  20. SHI X, Li J, Min B, Yang R, et al
    Application of ultrasound elastography for monitoring the effects of TbetaR1 shRNA therapy on hepatic fibrosis in a rat model.
    PLoS One. 2021;16:e0253150.
    PubMed         Abstract available

  21. REIMER RP, Hokamp NG, Niehoff J, Zopfs D, et al
    Value of spectral detector computed tomography for the early assessment of technique efficacy after microwave ablation of hepatocellular carcinoma.
    PLoS One. 2021;16:e0252678.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: